Details of the Drug Pharmacogenomic Perturbation Atlas

DEOXYCYTIDINE Drug Info

Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993

Cross-matching ID

PubChem CID

13711

ChEBI ID

CHEMBL15698

CAS Number

CAS 951-77-9

TTD Drug ID

D0RX7Z

General Information of Drug (ID: DMYE5LJ)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Fructose and mannose metabolism	2.05	1.15e-2	30/33 (90.91%)	AKR1B1;PFKP;SORD;...
Intestinal immune network for IgA production	2.01	5.74e-3	38/48 (79.17%)	CD40;TGFB1;HLA-DQB1;...
Pentose phosphate pathway	1.93	1.15e-2	25/30 (83.33%)	PFKP;PRPS1;GPI;...
Central carbon metabolism in cancer	1.88	1.43e-2	67/70 (95.71%)	PFKP;PGAM1;IDH2;...
Allograft rejection	1.86	1.38e-2	32/38 (84.21%)	CD40;HLA-DQB1;HLA-DPA1;...
Glutathione metabolism	1.83	1.53e-2	43/57 (75.44%)	ANPEP;IDH2;GGT1;...
DNA replication	1.78	2.79e-2	34/36 (94.44%)	RFC5;MCM5;RFC2;...
Galactose metabolism	1.77	2.58e-2	26/31 (83.87%)	AKR1B1;PFKP;PFKM;...
Cysteine and methionine metabolism	1.73	3.19e-2	43/50 (86%)	ADI1;MTAP;SRM;...
VEGF signaling pathway	1.70	4.13e-2	50/59 (84.75%)	PLA2G4A;SRC;BAD;...
Asthma	1.70	4.17e-2	25/31 (80.65%)	CD40;HLA-DQB1;HLA-DPA1;...
Bile secretion	-1.75	3.58e-2	68/90 (75.56%)	SLCO1B1;SLC22A7;SULT2A1;...
Mineral absorption	-1.81	2.65e-2	48/60 (80%)	CLCN2;ATP2B1;MT2A;...
Staphylococcus aureus infection	-1.81	3.10e-2	72/95 (75.79%)	FPR3;ITGB2;CFD;...
Coronavirus disease	-1.82	3.86e-2	215/232 (92.67%)	IFNA7;RPS28;EGFR;...
Legionellosis	-1.85	2.48e-2	51/57 (89.47%)	IL12A;BCL2L13;NFKB2;...
Complement and coagulation cascades	-2.59	0.00e+0	76/85 (89.41%)	F3;F13B;F8;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.04uM - 10uM	24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H